The Drug Enforcement Administration has been purchasing small quantities of controlled substances on the street and in undercover operations since 1979. For nearly fifty years, federal agents have paid street prices for heroin, cocaine, methamphetamine, and various other controlled substances, recorded the price, and sent the samples to forensic laboratories for purity analysis. The resulting dataset — the System to Retrieve Information from Drug Evidence, or STRIDE — is available to researchers and has been used in studies of drug market structure, the effectiveness of supply-side enforcement, and the economics of illegal markets.
What STRIDE also constitutes, examined from a different angle, is one of the longest-running, most methodologically consistent datasets on unregulated market pricing in existence. For nearly fifty years, federal agents have been tracking price and quality in markets that have no administered prices, no quarterly earnings management, no regulatory smoothing, and no political incentive to present a particular picture of economic conditions.
The DEA did not intend to build an economic monitoring program. But that is, among other things, what it built.
Why Drug Markets Are Informative
Before discussing what drug prices reveal, it's worth being clear about why drug markets are more informative than they might appear.
The standard objection to using illicit market data as economic signal is that these markets are too disrupted by law enforcement and supply-side shocks to carry reliable information about underlying economic conditions. A DEA interdiction that removes a significant cocaine shipment will spike cocaine prices regardless of what the GDP is doing. A drought in coca-producing regions of Colombia will reduce supply and raise prices independent of American consumer demand. The signal is noisy.
This objection is real but overstated. Supply-side shocks in drug markets — major interdictions, crop failures, cartel disruptions — are typically identifiable and can be accounted for. What remains after controlling for these shocks is a price signal that reflects demand conditions with a clarity that official data often cannot match.
Drug markets have several properties that make their price signals economically useful.
No price stickiness. In formal markets, prices are sticky. Retailers have promotional schedules, long-term supply contracts, and brand-equity considerations that prevent immediate price adjustment to changing conditions. Drug prices adjust continuously, constrained only by competitive pressure and the real-time economics of the transaction. When demand rises, prices rise. When supply is abundant, prices fall, or quality rises at a stable price. The market clears.
No institutional demand management. Corporations spend enormous resources managing demand perception — advertising, promotions, loyalty programs — to smooth consumer behavior and reduce price sensitivity. Drug markets have no such management. Demand expresses itself directly in price.
Quality adjustment as price signal. Drug purity is the most interesting variable in the dataset, because it functions as a real-time quality-adjustment mechanism. When a dealer faces higher wholesale costs but cannot raise retail prices without losing customers (price stickiness exists even in drug markets, driven by social relationships and competitive pressure), the adjustment mechanism is product adulteration. Purity falls while nominal price holds. This is drug-market shrinkflation — the same phenomenon that food manufacturers use when they reduce the weight of a product without changing the price. The effective cost to the buyer has risen; the nominal price hasn't.
Purity-adjusted price — the effective cost per unit of active ingredient — is a better measure of underlying market conditions than nominal price alone. And the purity-price relationship in drug markets tracks, with a lag, the same variables that drive formal-market pricing: input costs, supply constraints, competitive pressure, and demand.
Cocaine as Economic Sentiment Indicator
Among illegal drugs, cocaine occupies a specific economic position that makes it particularly informative as an indicator: it is a luxury recreational drug with elastic demand.
Unlike heroin, fentanyl, or methamphetamine — drugs with significant physical dependency components that drive demand independent of discretionary income — cocaine consumption tracks economic conditions in ways that mirror luxury consumer goods. Demand rises with disposable income, falls with economic stress, and is sensitive to price in ways that more dependency-driven substances are not.
This demand elasticity makes cocaine price and purity a reasonable proxy for discretionary consumer conditions at the top of the illicit drug market.
STRIDE data from the past several decades shows patterns that align meaningfully with economic cycles. During the economic expansion of the mid-to-late 1990s, cocaine purity at the retail level increased — supply was abundant, price competition was moderate, and buyers with disposable income were less tolerant of adulterated product. Nominal prices fell on a purity-adjusted basis through much of the expansion.
During the 2001–2002 recession, the pattern shifted. Purity declined in some markets even as nominal prices held relatively steady — the standard shrinkflation response to cost pressure. The purity-adjusted price of cocaine increased in the downturn even though the sticker price looked stable.
The 2007–2009 financial crisis produced a more dramatic version of the same pattern, compounded by a genuine supply shock from increased interdiction efforts and cartel disruption in Mexico. Disentangling supply-side effects from demand effects requires care, but the purity decline during this period — documented in DEA reports and academic research using STRIDE data — was real, and part of it reflected genuine reduction in the quality of product reaching retail markets under cost pressure.
This is shrinkflation in a market that has never encountered that word. It is also a measure, however imprecise, of economic conditions in the discretionary spending class of illicit consumption.
Methamphetamine and the Other Side of the Drug Economy
The cocaine story runs in parallel to a darker story about the other side of the illegal drug economy — one that has a very different relationship to economic conditions.
Methamphetamine is not a luxury drug. It is, among other things, functional: it suppresses appetite, extends wakefulness, and provides a stimulant effect that has historically made it attractive to people doing extended physical work in conditions of financial stress. Its user population has consistently skewed toward working-class and rural communities, and its demand profile is counter-cyclical in a specific way: it tends to rise during economic contractions, particularly in communities experiencing industrial decline.
The geographic expansion of methamphetamine use in the American Midwest and rural South during the 1990s and 2000s mapped closely onto the contraction of manufacturing employment in the same regions. The overlap was not perfect — drug distribution has its own geographic logic — but the correlation was strong enough to be documented in multiple academic studies. The drug served, among other functions, a labor-extension role in communities where multiple jobs, long shifts, and difficult physical work had become the economic norm.
Fentanyl's subsequent takeover of the illicit opioid market tells the darkest version of this story. The shift from heroin to fentanyl was, from the supply side, driven by economics: fentanyl is dramatically more potent per unit of weight, making it far cheaper to manufacture and transport relative to its psychoactive effect. But the demand-side adoption of a drug that requires extreme precision in dosing to avoid fatal overdose — and that has killed hundreds of thousands of Americans in the past decade — reflects something about the depth of economic desperation in the communities where it has spread.
People who have much to lose are cautious about existential risk. The tolerance for fentanyl's overdose risk, as revealed by the market's continued growth despite extensive public health campaigns and the availability of overdose reversal, is an indicator — uncomfortable and incomplete, but real — of how many people feel they have relatively little to lose.
This is not a comfortable piece of economic analysis. It is not presented as a comfortable piece of economic analysis. But the data is what it is.
The Silk Road Experiment
The most rigorous natural experiment in informal drug market price discovery came from an unexpected source: a darknet marketplace called Silk Road that operated on the Tor network from 2011 to 2013.
Silk Road allowed buyers and sellers to transact using Bitcoin, with a reputation system that provided quality assurance through buyer feedback, a dispute resolution mechanism, and a search and discovery infrastructure that the street market entirely lacks. It operated like a legitimate e-commerce platform — except that the primary product categories were controlled substances.
At its peak, Silk Road had several hundred thousand registered users and handled hundreds of millions of dollars in transactions. Nicolas Christin at Carnegie Mellon University, who studied the marketplace using listing data and transaction records before the FBI shut it down in October 2013, found something that should not have surprised an economist but surprised many observers.
Silk Road's prices were more efficient than street prices. Price dispersion — the variance in price across sellers offering equivalent products — was significantly lower than in street markets for the same substances. Prices adjusted to supply changes faster. Quality, as measured by buyer feedback, was higher and more consistent than street-market equivalents.
The explanation is straightforward. Street drug markets are characterized by severe information asymmetry (buyers cannot observe quality before purchase), high transaction risk (both parties to an illegal transaction face violence and arrest), and geographic fragmentation (prices differ block by block because there is no mechanism for arbitrage). Silk Road eliminated most of these frictions: reputation systems created verifiable quality signals, Bitcoin transactions eliminated many physical transaction risks, and a single marketplace enabled price discovery across a national market.
The result was a more efficient market. This is not an endorsement of illegal drug markets. It is a demonstration that the inefficiency of street drug markets is not inherent to illegal markets in general — it is a product of the specific information and transaction frictions that street markets impose. Remove those frictions and the market works, in the conventional sense of that word, quite well.
The implications for informal market price signals: the noisiness of street drug price data is not because illegal markets are inherently bad at finding prices. It is because street transaction infrastructure creates information asymmetry and friction that reduces signal quality. Where those frictions can be reduced or accounted for, the price signal from informal markets is meaningful.
The Purity-Price Ratio as Inflation Gauge
The most actionable insight from STRIDE data and drug market research is the purity-price ratio — the effective cost of the active substance per unit of consumption — as a more honest inflation measure than nominal price alone.
This metric is not tracked by any official statistical agency. But it has been computed by academic researchers using STRIDE data, and its behavior over time reveals patterns that align with formal-economy economic cycles in ways that nominal drug prices alone do not.
The purity-price ratio falls (meaning the effective cost per unit rises) during periods of supply disruption, economic contraction, and market stress. It rises (effective cost falls) during periods of supply abundance and economic expansion. This relationship is not clean — supply-side factors dominate over short periods — but over multi-year windows, the correlation with economic conditions is real.
If the BLS were to include purity-adjusted drug prices in its commodity price indices, it would have a real-time, continuous, unsmoothed measure of price behavior in the most price-sensitive, least institutionally mediated segment of consumer markets. The data would be messy. The political reception would be approximately what you'd expect. But the signal quality would be genuine.
The Honest Market
There is a persistent assumption in mainstream economics that legitimate markets are more efficient than black markets — that legal institutions, regulatory oversight, and contract enforcement make formal markets better at finding prices than informal ones. This assumption is largely wrong.
The efficiency of formal markets depends heavily on the quality of information, the absence of administered prices, and the absence of institutional actors with the resources to manipulate market signals. These conditions often do not hold. Corporate pricing is strategic and managed. Administered rates (central bank rates, regulated utility rates, government price controls) suppress price signals entirely in some sectors. Institutional actors in equity and commodity markets have documented histories of price manipulation.
Unregulated markets — drug markets, hawala networks, black markets for currency and goods — have their own distortions, particularly around violence and information asymmetry. But they do not have the specific distortions that formal markets introduce: no quarterly earnings management, no regulatory guidance on how prices should behave, no political pressure to present a particular picture of economic conditions.
The DEA's unintentional economic monitoring program — fifty years of price and purity data on some of the most price-sensitive markets in the economy — is, for a careful researcher, a window into economic conditions that official statistics cannot open. The window is dirty and the view is partial. But it looks out on something real.
FundScout connects small businesses with vetted commercial lenders — because the real economy that small businesses operate in is often more honestly described by informal signals than by the quarterly reports. This is the fourth in our series on the vice economy as financial signal.
Sources
- DEA System to Retrieve Information from Drug Evidence (STRIDE) — price and purity dataset collected since 1979; documented in Jonathan Caulkins, "The Distribution and Consumption of Illicit Drugs: Some Mathematical Models and Their Policy Implications", Carnegie Mellon University (1990)
- Jonathan P. Caulkins, "How Drug Enforcement Affects Drug Prices", Crime and Justice, Vol. 39, No. 1 (University of Chicago Press, 2010) — STRIDE methodology and drug price-purity analysis
- Nicolas Christin, "Traveling the Silk Road: A Measurement Analysis of a Large Anonymous Online Marketplace", Carnegie Mellon University (2012) — arxiv.org/abs/1207.7139; Silk Road operated 2011–2013; prices more efficient than street markets; price dispersion lower than street equivalents
- Silk Road FBI takedown (October 2013): U.S. Department of Justice press release, United States v. Ross William Ulbricht, Case 1:14-cr-00068 (S.D.N.Y.)
- Methamphetamine and manufacturing employment decline correlation — documented in Melissa S. Kearney, Benjamin Hyman, and Lauren Donahue, "The Supply and Demand of Rural Drug Abuse", Brookings Institution (2019); also Shannon M. Monnat and David L. Brown, "More Than a Rural Revolt: Landscapes of Despair and the 2016 Presidential Election", Journal of Rural Studies (2017)
- Fentanyl market expansion and overdose deaths — CDC National Center for Health Statistics, Drug Overdose Deaths in the United States (annual series) — cdc.gov